Alvotech Announces $150M Licensing And Commercialization Agreement With Lotus Pharmaceutical Plus Milestone Payments For Durvalumab, Emicizumab Biosimilars In U.S. And Eight Asian Markets

Loading news article.

Alvotech Announces $150M Licensing And Commercialization Agreement With Lotus Pharmaceutical Plus Milestone Payments For Durvalumab, Emicizumab Biosimilars In U.S. And Eight Asian Markets | WAPE

Alvotech Announces $150M Licensing And Commercialization Agreement With Lotus Pharmaceutical Plus Milestone Payments For Durvalumab, Emicizumab Biosimilars In U.S. And Eight Asian Markets

Article summary

Related companies

Comments —